Fenwick represented Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, in its $120 million Series C financing. The round was co-led by NEA, Abingworth and Forge Life Science Partners with participation from Avego, PFM Health Sciences, The Eleven Fund, The Column Group, 5AM Ventures, Redmile Group, Cowen Healthcare Investments, Sanofi Ventures, Osage University Partners (OUP) and Altitude Life Science Ventures.
Escient will use the new capital to advance the company’s pipeline of two first-in-class product candidates in several indications. More information can be obtained from the company’s announcement.
The transaction was led by corporate partners Effie Toshav and Ian Goldstein and associates Yashreeka Huq, Corinne Nhaissi and Tempestt Edward.